Melanotan 2 (MT-2)

Melanotan 2 (MT-2) is a synthetic peptide analog of alpha-melanocyte stimulating hormone (α- MSH), the hormone the body naturally produces to regulate skin pigmentation. By stimulating melanin production, MT-2 promotes skin darkening without requiring significant ultraviolet (UV) exposure, making it of considerable interest in dermatological, endocrinological, and cosmetic research.

Originally developed at the University of Arizona during the 1990s as a potential sunless tanning agent, researchers quickly discovered that MT-2 exhibited additional pharmacological effects on sexual arousal and appetite regulation. During early testing, one researcher famously experienced a prolonged eight-hour erection after accidentally injecting twice his intended dose, underscoring the compound’s potent activity at central nervous system melanocortin receptors.

MT-2 works by activating melanocortin receptors, particularly MC1R (responsible for pigmentation), MC3R, and MC4R (involved in sexual behavior, appetite, and energy balance). This broad receptor activation profile explains why MT-2 produces effects that extend well beyond tanning alone.

MT-2 is not approved by the US Food and Drug Administration (FDA) and is sold exclusively as a research compound. It has gained popularity in fitness, bodybuilding, and aesthetic communities as a method of achieving a deep tan without extensive sun exposure. It has also developed a following among individuals seeking enhanced libido.

The compound is administered via subcutaneous injection, typically following a loading phase and subsequent maintenance dosing schedule. Many users combine MT-2 with limited UV exposure to accelerate and deepen pigmentation results.

How It Works

Melanotan 2 exerts its effects through activation of multiple melanocortin receptors distributed throughout the body. Understanding these receptor pathways is essential for appreciating the compound’s diverse pharmacological profile.

MC1R (Melanocortin 1 Receptor) MC1R is located primarily on melanocytes, the pigment-producing cells within the skin. When MT-2 binds to MC1R, it initiates a signaling cascade that results in increased melanin synthesis. The melanin produced is subsequently transferred to surrounding keratinocytes (skin cells), causing the skin to gradually darken over a period of days to weeks. This mechanism effectively mimics the natural tanning process but without the requirement for extensive UV radiation exposure. MC3R and MC4R (Melanocortin 3 and 4 Receptors) MC3R and MC4R are located primarily in the central nervous system, where they play critical roles in the regulation of sexual behavior, appetite, and energy homeostasis. MC4R activation by MT-2 increases sexual arousal and enhances erectile response. Both MC3R and MC4R influence appetite regulation, frequently resulting in decreased hunger. These central receptor interactions explain the libido enhancement and appetite suppression that many users experience alongside pigmentation effects.

The Tanning Process

Unlike natural tanning, which requires UV radiation to stimulate melanocyte activity, MT-2 directly activates melanocytes through receptor binding. Key characteristics of the MT-2 tanning process include:

• Melanin production begins within days of initiating MT-2 administration
• Some UV exposure accelerates and deepens the pigmentation effect
• Pigmentation develops gradually over two to four weeks
• The tan can be maintained indefinitely with periodic maintenance doses
• Color fades gradually over weeks to months after discontinuation

Duration of Effects

MT-2’s effects on pigmentation are gradual and cumulative. Initial darkening may become visible within seven to ten days, with full effect typically developing over four to eight weeks of consistent use. Maintenance dosing can sustain results indefinitely, and pigmentation slowly fades over weeks to months following cessation.

Sexual effects, by contrast, are more immediate. They typically occur within hours of injection and persist for six to twenty-four or more hours, depending on the dose administered.

Research Benefits

Sunless Tanning

The primary benefit of MT-2 is the achievement of a tan with minimal UV exposure. Users report deep, natural-looking pigmentation with a significantly reduced need for sun or tanning bed exposure. Additionally, the protective melanin produced provides some degree of natural UV defense, and year-round tan maintenance is possible regardless of climate or seasonal sun availability.

Reduced UV Damage Risk

By achieving pigmentation with minimal UV exposure, MT-2 use may be associated with less cumulative sun damage, reduced risk of sunburn, potential reduction in photoaging, and a base tan that provides additional natural sun protection when UV exposure does occur.

Enhanced Libido and Sexual Function

Through MC3R and MC4R activation, MT-2 has been associated with increased sexual desire in both men and women, improved erectile function in men, and enhanced arousal and sexual response. These effects typically begin two to six hours after injection and represent a central nervous system-mediated mechanism distinct from peripheral vasodilators.

Appetite Suppression

Many users report decreased hunger and food cravings during MT-2 use. This effect may support easier adherence to calorie-restricted diets and offer potential benefits for weight management, though formal clinical evidence for this application remains limited.

Aesthetic Enhancement

In fitness and bodybuilding communities, MT-2 is valued for producing a darker skin tone that enhances visible muscle definition, provides a consistent appearance for competitions or photoshoots, and achieves an even tan without tan lines.

What the Science Shows

MT-2 has been investigated in clinical trials, though it was never brought to market for cosmetic use due to regulatory concerns. The following summarizes key findings from the available scientific literature.

Dorr et al. (1996) — Phase I Clinical Trial

Early human trials conducted at the University of Arizona evaluated subcutaneous MT-2 administration given daily for two weeks at doses ranging from 0.01 to 0.03 mg/kg. Two subjects showed increased facial, upper body, and buttock pigmentation one week after dosing ended. Results demonstrated that MT-2 produces measurable tanning with as few as five low doses given every other day. Reported side effects included nausea, flushing, and spontaneous erections lasting one to five hours.

Melanoma Risk

The question of whether MT-2 increases melanoma risk remains unresolved in the scientific literature. Case reports of melanoma in MT-2 users exist, but these cases coincide with heavy UV exposure. A 2013 review found no conclusive evidence that MT-2 causes melanoma. A 2021

review concluded that the increased melanoma risk observed in users was likely explained by greater UV exposure habits rather than MT-2 itself. Notably, a 2020 study found that MT-2 actually suppressed melanoma progression in a mouse model.

Mole Darkening

MT-2 causes reversible darkening of existing moles and freckles. This effect is well documented and expected. Pigment intensity returns to baseline after discontinuation. Users are advised to monitor moles for irregular changes such as asymmetry, border irregularity, color variation, or diameter changes, and professional dermatological screening is recommended before and during use.

Sexual Function Research

MT-2’s effects on sexual function are well established and led directly to the development of PT- 141 (bremelanotide), a related peptide that is now FDA approved for the treatment of hypoactive sexual desire disorder in premenopausal women. The mechanisms of sexual enhancement have been confirmed to operate through central nervous system pathways rather than peripheral blood flow mechanisms, affecting both desire and physical response.

Dosing Protocol

MT-2 dosing follows a loading and maintenance pattern. Dosing varies considerably based on individual goals, skin type, and sensitivity. Fair-skinned individuals may observe dramatic changes at lower doses, while those with darker baseline skin may require higher doses for noticeable effect.

Loading Phase

Week Dose Frequency Notes 1 0.25 mg Daily Assess tolerance 2–4 0.5 mg Daily Standard loading dose 5–8 0.5–1.0 mg Daily Continue until desired color is achieved

Maintenance Phase

Once desired pigmentation is achieved, users transition to maintenance dosing:

Protocol Dose Frequency Conservative 0.5 mg 1 to 2 times weekly Standard 0.5–1.0 mg 1 to 2 times weekly

Skin Type Considerations

• Very Fair (Fitzpatrick Type I–II): Start at the lower end (0.25 mg); expect dramatic

pigmentation change

• Medium (Fitzpatrick Type III–IV): Standard dosing applies; moderate pigmentation

change expected

• Olive/Darker (Fitzpatrick Type V–VI): May require higher doses for noticeable effect

UV Exposure Guidelines

Many protocols incorporate limited UV exposure to enhance results:

• 10 to 15 minutes of natural sun or tanning bed exposure during the loading phase
• UV exposure accelerates and deepens melanin development
• Significantly less UV is needed compared to natural tanning
• Avoid burning at all times; the goal is gentle melanocyte activation

Sexual Enhancement Dosing

For libido effects specifically, a dose of 0.5 to 1.0 mg is administered two to four hours before anticipated activity. Effects typically last twelve to twenty-four or more hours. MT-2 can be used on an as-needed basis for this indication.

Draw Volumes by Vial Size

10 mg Vial (reconstituted with 2 mL bacteriostatic water = 5 mg/mL concentration):

Dose Volume Syringe Units Vial Duration 0.25 mg 0.05 mL 5 units 40 doses 0.50 mg 0.10 mL 10 units 20 doses 0.75 mg 0.15 mL 15 units ~13 doses 1.0 mg 0.20 mL 20 units 10 doses

At 0.5 mg daily for loading, one 10 mg vial provides approximately 20 days of dosing. At 0.5 mg twice weekly for maintenance, one 10 mg vial provides approximately 10 weeks of dosing.

Reconstitution Instructions

1. Remove the plastic cap from the vial and wipe the rubber stopper with an alcohol swab. 2. Draw 2 mL of bacteriostatic water into a sterile syringe. 3. Insert the needle through the rubber stopper at an angle. 4. Direct the stream of water down the inside wall of the vial slowly to avoid disturbing the lyophilized powder. 5. Allow the peptide to dissolve without shaking. Gentle swirling is acceptable. 6. Once fully dissolved, the solution should appear clear and colorless. 7. Label the vial with the date and concentration (5 mg/mL).

MT-2 dissolves readily. If the solution appears cloudy or discolored, do not use it.

Side Effects

Common Side Effects

• Nausea: The most frequently reported side effect, especially during initial use or at

higher doses. Nausea typically decreases with continued dosing.

• Facial Flushing: Temporary warmth and redness of the face, generally mild and self-

resolving.

• Fatigue or Drowsiness: Some users report transient tiredness following injection.
• Headache: Occasionally reported, typically mild.
• Spontaneous Erections: In men, erections may occur without sexual stimulation and can

be pronounced.

• Decreased Appetite: A consistent finding related to central melanocortin receptor

activation.

Characteristic Effects

• Darkening of existing moles and freckles (reversible upon discontinuation)
• Darkening of lips and gums (reversible)
• Appearance of new freckles in some individuals
• Increased libido

Serious Concerns

• Unknown long-term effects on melanoma risk
• Hyperpigmentation in undesired areas
• Potential cardiovascular effects, including blood pressure changes
• Mood changes reported in some users

Nausea Management Strategies

• Begin with lower doses (0.25 mg) and increase gradually
• Administer injections in the evening before bed to sleep through the peak nausea window

(two to four hours post-injection)

• Use anti-nausea medication if necessary
• Nausea typically improves after the first one to two weeks of use

Contraindications and Precautions

Individuals Who Should Avoid MT-2

• Individuals with a personal history of melanoma or atypical moles
• Those with a family history of melanoma
• Pregnant or breastfeeding women
• Individuals with significant cardiovascular disease
• Those with uncontrolled hypertension

Individuals Who Should Use with Caution

• Those with numerous moles (regular monitoring required)
• Fair-skinned individuals (start with low doses and monitor for over-pigmentation)
• People prone to freckling (may develop new freckles)
• Anyone with autoimmune conditions affecting the skin

Mole Monitoring Protocol

All individuals using MT-2 should:

• Document existing moles with photographs before initiating use
• Monitor moles regularly for asymmetry, border irregularity, color changes, and diameter

changes (the ABCD criteria)

• Seek professional dermatological evaluation if any mole develops concerning

characteristics

• Understand that mole darkening is expected with MT-2 use and is generally reversible

upon discontinuation

Comparison to Similar Compounds

Compound Primary Effect Libido Effect Appetite Effect Selectivity Melanotan 2 Tanning + Libido Strong Suppresses Non-selective Melanotan 1 Tanning only Minimal Minimal MC1R selective PT-141 Libido only Strong None MC3R/MC4R

Melanotan 1 (MT-1, Afamelanotide) Melanotan 1 is more selective for MC1R and produces tanning without significant libido or appetite effects. It is FDA approved under the brand name Scenesse for the treatment of erythropoietic protoporphyria, a rare photosensitivity disorder. MT-1 has a more favorable safety profile than MT-2 but is less potent and considerably more expensive.

PT-141 (Bremelanotide) PT-141 was developed directly from MT-2 research and was specifically optimized for the treatment of sexual dysfunction. It has been isolated to target MC3R and MC4R without producing significant pigmentation effects. PT-141 is FDA approved under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. For individuals seeking libido enhancement without tanning effects, PT-141 is the more appropriate choice.

Success Tips

Start Low

Begin with 0.25 mg to assess individual tolerance, particularly regarding nausea. The dose can always be increased; the effects of an overly large initial dose cannot be undone.

Evening Dosing

Administer injections in the evening before bed. This allows users to sleep through the peak nausea window (two to four hours post-injection) and, for men, often through the spontaneous erection period.

Gradual Approach

MT-2 effects are cumulative, and there is no advantage to aggressive loading. A slower, steady approach produces more even pigmentation and fewer side effects than rapid dose escalation.

Minimal UV Exposure

Significant sun exposure is not required for MT-2 to produce results. Ten to fifteen minutes of natural sun or five to ten minutes of tanning bed exposure is sufficient. UV activates and deepens the pigment but is not an absolute requirement. Users should never allow themselves to burn; the objective is gentle melanocyte activation.

Rotate Injection Sites

Change injection sites with each administration to prevent irritation or the development of subcutaneous lumps. Recommended injection sites include the lower abdomen, upper thigh, and back of the upper arm.

Maintain Health Fundamentals

MT-2 alters skin appearance but does not replace foundational health practices. Users should continue to prioritize adequate sleep, proper nutrition, hydration, and regular exercise.

Storage and Handling

Before Reconstitution

• Store lyophilized (powder) vials in the freezer at −20°C
• Protect from light
• Stable for extended periods when properly frozen

After Reconstitution

• Refrigerate at 2°C to 8°C
• Use within one to two weeks for optimal potency
• Protect from light
• Do not freeze after reconstitution
• Discard if the solution becomes cloudy or discolored

MT-2 is relatively stable but degrades faster than some peptides once reconstituted. It is advisable to prepare only the amount that will be used within one to two weeks.

Legal Status

United States

MT-2 is not FDA approved for any indication. It is sold as a research compound and is not approved for human use. The FDA has issued warnings regarding the use of unlicensed tanning injections.

International

Legal status varies by country. MT-2 is generally considered unregulated or available for research purposes in many jurisdictions. Numerous national health agencies advise against use due to the lack of formal regulatory approval.

Frequently Asked Questions

How long until I see results?

Initial darkening is often visible within seven to ten days. Full effect develops over four to eight weeks of consistent use. Results vary based on skin type and dosing.

Do I need to use tanning beds or sun exposure?

UV exposure accelerates and deepens the effect but is not strictly required. MT-2 will produce some pigmentation without UV, but most users incorporate limited sun or tanning bed exposure for optimal results.

Will my moles change?

Yes. Existing moles and freckles typically darken during MT-2 use. This is a normal, expected, and reversible effect. However, users should monitor moles for any irregular changes (asymmetry, border irregularity, color variation, diameter changes) and consult a dermatologist if concerned.

Is the tan permanent?

No. Pigmentation gradually fades over weeks to months after discontinuing MT-2. Maintenance dosing of once or twice weekly can sustain results indefinitely.

Why do I experience nausea?

Nausea is a common side effect, especially at higher doses or early in use. It typically improves with continued dosing. Evening administration (to sleep through peak nausea) and starting at lower doses help manage this side effect.

Can women use MT-2?

Yes. Women experience similar tanning and libido effects. The same dosing principles apply. Women should be aware that MT-2 may darken the nipples and areolas more noticeably than other areas.

How is MT-2 different from PT-141?

MT-2 was the original compound and produces multiple effects, including tanning, libido enhancement, and appetite suppression. PT-141 was developed from MT-2 research specifically for sexual function and has minimal pigmentation effects. For individuals seeking libido enhancement without tanning, PT-141 is the more appropriate option.

References

8. Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996;58(20):1777– 1784. 9. Levine N, Sheftel SN, Eytan T, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 1991;266(19):2730–2736. 10. Hruby VJ, Sharma SD, Toth K, et al. Design, synthesis, and conformation of superpotent and prolonged acting melanotropins. Annals of the New York Academy of Sciences. 1993;680:51–63. 11. Brzoska T, Luger TA, Maaser C, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews. 2008;29(5):581–602. 12. Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology. 2012;50(10):1169–1173.